Erectile dysfunction is a common complication of spinal cord injury. Of the 68 spinal cord injured men in whom treatment with papaverine was initiated a therapeutic dosage was determined in 50 (74%). Papaverine was injected into the base of one corpora cavernosum. The dose started at 3 mg and was increased at weekly or longer intervals until an effective dose was determined. There were 15 (30%) men with tetraplegia and 35 (70%) men with paraplegia. The dosage of papaverine did not relate to the level or extent of injury. Doses of 12 mg or less were used in 56% of patients. Low dose papaverine is a safe and effective means of restoring erections in spinal cord injured men.
Introduction
Erectile dysfunction is a common complication of spinal cord injury. Several methods exist to manage this problem in spinal cord injured men seeking treat ment.1-3 In our center intracavernous injection of vasoactive substances, vacuum tumescene constriction therapy and penile prostheses are available treatment options. All available methods are described to' the patient and demonstrated via video tape. After discus sing the risks and benefits of each technique the patient can choose the technique he prefers if there are no medical contraindications. Informed consent is re quired prior to intracavernous injections. This paper reports on our experience using papaverine to restore erections in spinal cord injured males.
Methods
After being made aware of the options available and the possible risks 68 spinal cord injured men chose intracorporeal injections of a vasoactive substance to treat their erectile dysfunction. Erectile dysfunction refers to the inability to get an erection, or a reflex erection which is not satisfactory for intercourse. Initial doses of 3 mg of papaverine were injected into the base of one corpora cavernosum. If there was no response or an unsatisfactory response the patient returned to the clinic for follow-up attempts of a higher dosage at weekly or longer intervals. The dose was increased by Due to a lack of response at lower doses six men had their increases in dose accelerated in increments larger than 3 mg per trial. A T6 paraplegic patient had the dose increased to 30 mg in three doses, a C6 tetraplegic responded at 90 mg in nine doses, and a C7 tetraplegic responded to 30 mg after five sessions. Three persons were initiated at higher than the currently used doses Eleven men did not complete the protocol after one or more injections. Three switched to vacuum tumes cence constriction therapy and three required papa verine and phentolamine in combination. 
